source
- Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.onclive · 2mo ago↗ source
- Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEAZanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.onclive · 2mo ago↗ source
- Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy ResponseLearn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.